Cagrilintide
Adults without diabetes · SubQ · 2021 phase 2 monotherapy trial
Five separate SubQ dose arms from the 2021 monotherapy trial. Cagrilintide alone and CagriSema have different study protocols.
Peptide dosing library
Browse peptide dose references, source-linked schedules and downloadable charts. Explore the science with myPeptides. – Page 2
Cardiogen
Patent experiments · No established human dosing schedule
Cardiogen is an AEDR tetrapeptide studied in preclinical material. There is no established human cardiac dosing schedule. Patent experiments · No established human dosing schedule.
Cartalax
Cell culture · No established human dosing schedule
Cartalax is an AED tripeptide investigated in cartilage-related cell research. Human dose and treatment frequency remain unestablished. Cell culture · No established human dosing schedule.
Cerebrolysin
Adults · Austrian Cerebrolysin product information · IV regimens
Cerebrolysin is a defined porcine-brain peptide preparation. These volumes refer to the Austrian medicinal product. Adults · Austrian Cerebrolysin product information · IV regimens.
Chonluten
Cell culture · No established human dosing schedule
Chonluten is the EDG tripeptide. Its cell experiments do not establish a human dose or support borrowing a Bronchogen regimen. Cell culture · No established human dosing schedule.
CJC-1295 DAC
Healthy adults · SubQ phase 1 dose-finding · Teichman 2006
CJC-1295 DAC is a long-acting GHRH analogue. This card shows selected single-dose cohorts in healthy adults. Healthy adults · SubQ phase 1 dose-finding · Teichman 2006.
CJC-1295 (no DAC)
Exact-formulation gap · No established human dosing schedule
CJC-1295 without DAC is commonly called modified GRF 1-29. The long-acting CJC-1295 trial does not establish its dose. Exact-formulation gap · No established human dosing schedule.
Cortagen
Animal nerve models · No established human dosing schedule
Cortagen is the AEDP tetrapeptide investigated in nerve-injury models. Those models do not establish a human dosing course. Animal nerve models · No established human dosing schedule.
Crystagen
Tissue experiments · No established human dosing schedule
Crystagen is the EDP tripeptide examined in immune-tissue models. A clinically supported human dosing schedule is missing. Tissue experiments · No established human dosing schedule.
Dihexa
Preclinical / uncertain · No established human dosing schedule
Dihexa is an experimental angiotensin-derived molecule. Human dosing cannot be inferred from rodent memory experiments. Preclinical / uncertain · No established human dosing schedule.
DSIP
Chronic insomnia · Small blinded sleep-laboratory study · Bes 1992
DSIP was investigated in small sleep studies. This reference records an intravenous experiment, not a SubQ sleep protocol. Chronic insomnia · Small blinded sleep-laboratory study · Bes 1992.
Dulaglutide
Adults · Type 2 diabetes · US Trulicity label, March 2026
The US Trulicity adult type 2 diabetes schedule, with optional increases only when additional glycaemic control is needed.